Ameya Rejeev Kirtane, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Delivery Systems | 15 | 2023 | 2219 | 1.830 |
Why?
|
| Drug Carriers | 6 | 2021 | 693 | 1.450 |
Why?
|
| Nanoparticles | 9 | 2023 | 1905 | 1.070 |
Why?
|
| Nanotechnology | 3 | 2021 | 710 | 0.900 |
Why?
|
| Oils | 1 | 2022 | 63 | 0.840 |
Why?
|
| Food | 2 | 2022 | 771 | 0.710 |
Why?
|
| Phenanthrenes | 2 | 2017 | 63 | 0.670 |
Why?
|
| Laurates | 1 | 2017 | 9 | 0.610 |
Why?
|
| Monoglycerides | 1 | 2017 | 10 | 0.610 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2015 | 281 | 0.600 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2017 | 63 | 0.590 |
Why?
|
| Contraceptives, Oral | 1 | 2019 | 564 | 0.590 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 215 | 0.540 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2015 | 91 | 0.510 |
Why?
|
| Vaccines | 1 | 2023 | 822 | 0.500 |
Why?
|
| Fibrin | 1 | 2017 | 506 | 0.480 |
Why?
|
| Albumins | 1 | 2017 | 569 | 0.480 |
Why?
|
| Nanomedicine | 1 | 2017 | 304 | 0.470 |
Why?
|
| Melanoma, Experimental | 1 | 2017 | 561 | 0.450 |
Why?
|
| Pyridones | 1 | 2018 | 712 | 0.440 |
Why?
|
| Swine | 10 | 2024 | 5917 | 0.430 |
Why?
|
| Polymers | 4 | 2020 | 1621 | 0.430 |
Why?
|
| Communicable Diseases | 1 | 2021 | 880 | 0.420 |
Why?
|
| Gastrointestinal Tract | 5 | 2023 | 814 | 0.410 |
Why?
|
| Anti-HIV Agents | 2 | 2018 | 4256 | 0.400 |
Why?
|
| Capillary Permeability | 1 | 2015 | 798 | 0.390 |
Why?
|
| Luminescent Proteins | 1 | 2013 | 853 | 0.370 |
Why?
|
| Dosage Forms | 3 | 2019 | 56 | 0.370 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 1261 | 0.370 |
Why?
|
| Paclitaxel | 2 | 2017 | 1708 | 0.360 |
Why?
|
| Cyanides | 2 | 2020 | 83 | 0.340 |
Why?
|
| Guanidines | 2 | 2020 | 193 | 0.330 |
Why?
|
| Transfection | 2 | 2014 | 5892 | 0.330 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 1873 | 0.310 |
Why?
|
| Administration, Oral | 7 | 2019 | 3913 | 0.300 |
Why?
|
| Delayed-Action Preparations | 4 | 2020 | 968 | 0.290 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 2158 | 0.290 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 1715 | 0.290 |
Why?
|
| Lung Neoplasms | 5 | 2017 | 13102 | 0.270 |
Why?
|
| Nanocapsules | 2 | 2016 | 91 | 0.250 |
Why?
|
| Animals | 29 | 2024 | 168757 | 0.250 |
Why?
|
| Antiviral Agents | 1 | 2017 | 2987 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2016 | 13695 | 0.240 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2021 | 1375 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2021 | 3557 | 0.230 |
Why?
|
| Excipients | 2 | 2021 | 96 | 0.230 |
Why?
|
| Adhesives | 1 | 2023 | 61 | 0.220 |
Why?
|
| Mucous Membrane | 2 | 2023 | 673 | 0.220 |
Why?
|
| Neoplasms | 4 | 2016 | 21683 | 0.210 |
Why?
|
| Models, Biological | 2 | 2016 | 9583 | 0.200 |
Why?
|
| Gels | 1 | 2022 | 427 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2023 | 634 | 0.190 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2020 | 86 | 0.180 |
Why?
|
| Diterpenes | 2 | 2020 | 173 | 0.180 |
Why?
|
| Immunity, Mucosal | 1 | 2023 | 490 | 0.180 |
Why?
|
| Glucuronides | 1 | 2019 | 20 | 0.180 |
Why?
|
| Levonorgestrel | 1 | 2019 | 77 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 4 | 2024 | 1071 | 0.170 |
Why?
|
| Drug Interactions | 2 | 2024 | 1460 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5172 | 0.160 |
Why?
|
| Water | 2 | 2022 | 1395 | 0.160 |
Why?
|
| Curcumin | 1 | 2019 | 96 | 0.160 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 6314 | 0.160 |
Why?
|
| Intestine, Small | 2 | 2023 | 1241 | 0.160 |
Why?
|
| Radiation Protection | 1 | 2021 | 419 | 0.150 |
Why?
|
| Stomach | 2 | 2019 | 697 | 0.150 |
Why?
|
| Administration, Intravaginal | 1 | 2017 | 150 | 0.150 |
Why?
|
| Biological Availability | 4 | 2024 | 397 | 0.140 |
Why?
|
| Contraceptive Devices, Female | 1 | 2016 | 43 | 0.140 |
Why?
|
| NAD | 1 | 2020 | 593 | 0.140 |
Why?
|
| Oxazines | 1 | 2018 | 298 | 0.140 |
Why?
|
| Rheology | 1 | 2017 | 345 | 0.140 |
Why?
|
| Intestines | 2 | 2024 | 1924 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2023 | 934 | 0.140 |
Why?
|
| Lignans | 1 | 2016 | 81 | 0.140 |
Why?
|
| Drug Design | 3 | 2021 | 1076 | 0.140 |
Why?
|
| Fibrinolysis | 1 | 2017 | 322 | 0.130 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 601 | 0.130 |
Why?
|
| Anopheles | 1 | 2018 | 197 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 944 | 0.130 |
Why?
|
| Biological Transport | 3 | 2014 | 2118 | 0.120 |
Why?
|
| Technology, Pharmaceutical | 1 | 2015 | 84 | 0.120 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 599 | 0.120 |
Why?
|
| Porosity | 1 | 2015 | 362 | 0.120 |
Why?
|
| Surface-Active Agents | 1 | 2014 | 159 | 0.120 |
Why?
|
| Cytokines | 2 | 2020 | 7322 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2021 | 1180 | 0.120 |
Why?
|
| Particle Size | 2 | 2015 | 1642 | 0.110 |
Why?
|
| Solubility | 1 | 2015 | 1085 | 0.110 |
Why?
|
| Humans | 28 | 2024 | 744343 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2017 | 627 | 0.110 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2018 | 871 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 1 | 2014 | 253 | 0.110 |
Why?
|
| Mice, Nude | 2 | 2019 | 3689 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 849 | 0.110 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2017 | 570 | 0.110 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 624 | 0.110 |
Why?
|
| Biocompatible Materials | 2 | 2019 | 1736 | 0.110 |
Why?
|
| Biphenyl Compounds | 1 | 2016 | 913 | 0.100 |
Why?
|
| Hydrogels | 1 | 2017 | 724 | 0.100 |
Why?
|
| Vagina | 1 | 2017 | 825 | 0.100 |
Why?
|
| Simian immunodeficiency virus | 1 | 2017 | 846 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 4933 | 0.100 |
Why?
|
| Mice | 10 | 2024 | 81183 | 0.100 |
Why?
|
| Vaccination | 1 | 2023 | 3278 | 0.100 |
Why?
|
| Antimalarials | 1 | 2018 | 905 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2023 | 13033 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2214 | 0.090 |
Why?
|
| Macaca mulatta | 1 | 2017 | 2375 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 3586 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 8863 | 0.080 |
Why?
|
| Malaria | 1 | 2018 | 1239 | 0.080 |
Why?
|
| Forecasting | 1 | 2016 | 2951 | 0.070 |
Why?
|
| Piperazines | 1 | 2018 | 2488 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2018 | 2684 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4253 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2727 | 0.070 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 16689 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1376 | 0.070 |
Why?
|
| Hexuronic Acids | 2 | 2017 | 144 | 0.070 |
Why?
|
| Glucuronic Acid | 2 | 2017 | 148 | 0.070 |
Why?
|
| Indoles | 1 | 2014 | 1839 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3703 | 0.070 |
Why?
|
| Nitrosamines | 2 | 2016 | 87 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3589 | 0.070 |
Why?
|
| Folic Acid | 1 | 2012 | 1300 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2020 | 3481 | 0.060 |
Why?
|
| Biological Assay | 2 | 2020 | 652 | 0.060 |
Why?
|
| Alginates | 2 | 2017 | 252 | 0.060 |
Why?
|
| Female | 11 | 2021 | 380194 | 0.060 |
Why?
|
| Tissue Distribution | 2 | 2021 | 2327 | 0.060 |
Why?
|
| Genotype | 1 | 2018 | 12951 | 0.060 |
Why?
|
| Diffusion | 2 | 2016 | 833 | 0.060 |
Why?
|
| Glioma | 1 | 2018 | 3401 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 2635 | 0.060 |
Why?
|
| Cell Survival | 3 | 2017 | 5882 | 0.050 |
Why?
|
| Taurocholic Acid | 1 | 2021 | 43 | 0.050 |
Why?
|
| Glycyrrhizic Acid | 1 | 2021 | 11 | 0.050 |
Why?
|
| Skin Absorption | 1 | 2021 | 94 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 6386 | 0.050 |
Why?
|
| HIV Infections | 2 | 2017 | 16718 | 0.050 |
Why?
|
| Tretinoin | 1 | 2023 | 517 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2020 | 276 | 0.040 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 128 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2022 | 41006 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2021 | 346 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 393 | 0.040 |
Why?
|
| Acrylamides | 1 | 2020 | 255 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 21827 | 0.040 |
Why?
|
| Veterinary Medicine | 1 | 2018 | 21 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2021 | 1827 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2014 | 3752 | 0.040 |
Why?
|
| Candida albicans | 1 | 2021 | 394 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 23403 | 0.040 |
Why?
|
| Glucuronidase | 1 | 2019 | 207 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 3505 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 268 | 0.040 |
Why?
|
| Magnolia | 1 | 2016 | 1 | 0.040 |
Why?
|
| Acrylic Resins | 1 | 2017 | 142 | 0.040 |
Why?
|
| Epoxy Compounds | 1 | 2017 | 136 | 0.040 |
Why?
|
| Cell Movement | 2 | 2020 | 5217 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 5256 | 0.040 |
Why?
|
| Epithelium | 1 | 2020 | 1679 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2021 | 6196 | 0.030 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2014 | 91 | 0.030 |
Why?
|
| Singlet Oxygen | 1 | 2014 | 53 | 0.030 |
Why?
|
| Models, Chemical | 1 | 2016 | 626 | 0.030 |
Why?
|
| Methylene Blue | 1 | 2014 | 155 | 0.030 |
Why?
|
| Child | 1 | 2022 | 77709 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 29786 | 0.030 |
Why?
|
| Materials Testing | 1 | 2017 | 867 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2014 | 446 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2014 | 242 | 0.030 |
Why?
|
| Esophagus | 1 | 2019 | 1019 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2016 | 471 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2716 | 0.030 |
Why?
|
| Rats | 2 | 2021 | 24260 | 0.030 |
Why?
|
| Temperature | 1 | 2019 | 2206 | 0.030 |
Why?
|
| Autophagy | 1 | 2020 | 1300 | 0.030 |
Why?
|
| Absorption | 1 | 2012 | 248 | 0.030 |
Why?
|
| Bronchi | 1 | 2016 | 840 | 0.030 |
Why?
|
| Carcinogens | 1 | 2014 | 466 | 0.030 |
Why?
|
| Piperidines | 1 | 2020 | 1602 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 1584 | 0.030 |
Why?
|
| Rabbits | 1 | 2018 | 4894 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 387 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2020 | 4217 | 0.020 |
Why?
|
| Liposomes | 1 | 2014 | 759 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2017 | 10481 | 0.020 |
Why?
|
| Polyglycolic Acid | 1 | 2012 | 407 | 0.020 |
Why?
|
| Kinetics | 1 | 2018 | 6473 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2017 | 1538 | 0.020 |
Why?
|
| Apoptosis | 2 | 2017 | 9727 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 18029 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 738 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2014 | 602 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 4665 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 8301 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 1213 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2282 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2967 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2014 | 807 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4386 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1133 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
| Macrophages | 1 | 2020 | 5655 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2014 | 5078 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2020 | 7880 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2017 | 19229 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2012 | 3036 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2012 | 3690 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13284 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20129 | 0.010 |
Why?
|
| Algorithms | 1 | 2017 | 13881 | 0.010 |
Why?
|
| Lung | 1 | 2014 | 9856 | 0.010 |
Why?
|
| Male | 3 | 2018 | 350118 | 0.010 |
Why?
|
| United States | 1 | 2020 | 69872 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 20822 | 0.010 |
Why?
|